This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Investors who clued into the potential of Pharmacyclics' experimental B-cell lymphoma drug PCI-32765 last year were rewarded big time this year when
Johnson & Johnson(JNJ) paid handsomely to secure licensing rights to the drug in December.
The stock: Pharmacyclics is up 140% this year through Dec. 16. The stock's performance this year, particularly two strong runs in the spring and late fall, illustrate how investors love to buy biotech stocks ahead of big drug research meetings.
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.